CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug
conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study
is that CD46 expression, measured via our novel imaging biomarker, is a characteristic
feature of mCRPC, and particularly common in the most lethal forms of the disease including
adenocarcinoma and Small-cell neuroendocrine carcinoma (SCNC). These data will provide
crucial information about the feasibility of targeting cluster of differentiation 46 (CD46)
in mCRPC, will be used guide the development of novel therapeutic and theranostic agents, to
help develop treatments that improve outcomes for men with the most lethal forms of prostate
cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Robert Flavell, MD, PhD
Collaborators:
Fortis Therapeutics, Inc. United States Department of Defense